495 related articles for article (PubMed ID: 32183332)
1. Biochemical Markers in Alzheimer's Disease.
Rabbito A; Dulewicz M; Kulczyńska-Przybik A; Mroczko B
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183332
[TBL] [Abstract][Full Text] [Related]
2. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease.
Pereira JB; Westman E; Hansson O;
Neurobiol Aging; 2017 Oct; 58():14-29. PubMed ID: 28692877
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.
Mattsson N; Insel PS; Palmqvist S; Portelius E; Zetterberg H; Weiner M; Blennow K; Hansson O;
EMBO Mol Med; 2016 Oct; 8(10):1184-1196. PubMed ID: 27534871
[TBL] [Abstract][Full Text] [Related]
4. Applying fluid biomarkers to Alzheimer's disease.
Zetterberg H
Am J Physiol Cell Physiol; 2017 Jul; 313(1):C3-C10. PubMed ID: 28424166
[TBL] [Abstract][Full Text] [Related]
5. Strategies for improving the postmortem neuropathological diagnosis of Alzheimer's disease.
Trojanowski JQ; Clark CM; Schmidt ML; Arnold SE; Lee VM
Neurobiol Aging; 1997; 18(4 Suppl):S75-9. PubMed ID: 9330990
[TBL] [Abstract][Full Text] [Related]
6. The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease.
Kvartsberg H; Lashley T; Murray CE; Brinkmalm G; Cullen NC; Höglund K; Zetterberg H; Blennow K; Portelius E
Acta Neuropathol; 2019 Jan; 137(1):89-102. PubMed ID: 30244311
[TBL] [Abstract][Full Text] [Related]
7. Biological markers in Alzheimer's disease.
Grundke-Iqbal I; Rolkova G; Konstekova E; Iqbal K
Bratisl Lek Listy; 2006; 107(9-10):359-65. PubMed ID: 17262988
[TBL] [Abstract][Full Text] [Related]
8. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease.
Prvulovic D; Hampel H
Clin Chem Lab Med; 2011 Mar; 49(3):367-74. PubMed ID: 21342022
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic dysfunction, and axonal injury relate to atrophy in structural brain regions specific to Alzheimer's disease.
Moore EE; Gifford KA; Khan OA; Liu D; Pechman KR; Acosta LMY; Bell SP; Turchan M; Landman BA; Blennow K; Zetterberg H; Hohman TJ; Jefferson AL
Alzheimers Dement; 2020 Jun; 16(6):883-895. PubMed ID: 32378327
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum.
Bos I; Vos S; Verhey F; Scheltens P; Teunissen C; Engelborghs S; Sleegers K; Frisoni G; Blin O; Richardson JC; Bordet R; Tsolaki M; Popp J; Peyratout G; Martinez-Lage P; Tainta M; Lleó A; Johannsen P; Freund-Levi Y; Frölich L; Vandenberghe R; Westwood S; Dobricic V; Barkhof F; Legido-Quigley C; Bertram L; Lovestone S; Streffer J; Andreasson U; Blennow K; Zetterberg H; Visser PJ
Alzheimers Dement; 2019 May; 15(5):644-654. PubMed ID: 30853464
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer's disease pathogenesis.
Dhiman K; Blennow K; Zetterberg H; Martins RN; Gupta VB
Cell Mol Life Sci; 2019 May; 76(10):1833-1863. PubMed ID: 30770953
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's disease markers in the aged sheep (Ovis aries).
Reid SJ; Mckean NE; Henty K; Portelius E; Blennow K; Rudiger SR; Bawden CS; Handley RR; Verma PJ; Faull RLM; Waldvogel HJ; Zetterberg H; Snell RG
Neurobiol Aging; 2017 Oct; 58():112-119. PubMed ID: 28728117
[TBL] [Abstract][Full Text] [Related]
13. CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD.
Blennow K; Diaz-Lucena D; Zetterberg H; Villar-Pique A; Karch A; Vidal E; Hermann P; Schmitz M; Ferrer Abizanda I; Zerr I; Llorens F
J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):846-853. PubMed ID: 31097472
[TBL] [Abstract][Full Text] [Related]
14. A review of genome mutation and Alzheimer's disease.
Thomas P; Fenech M
Mutagenesis; 2007 Jan; 22(1):15-33. PubMed ID: 17158517
[TBL] [Abstract][Full Text] [Related]
15. Molecular biomarkers of Alzheimer's disease: progress and prospects.
Lashley T; Schott JM; Weston P; Murray CE; Wellington H; Keshavan A; Foti SC; Foiani M; Toombs J; Rohrer JD; Heslegrave A; Zetterberg H
Dis Model Mech; 2018 May; 11(5):. PubMed ID: 29739861
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid biomarkers for Alzheimer's disease: current limitations and recent developments.
Zetterberg H
Curr Opin Psychiatry; 2015 Sep; 28(5):402-9. PubMed ID: 26147615
[TBL] [Abstract][Full Text] [Related]
17. [Markers of prodromal Alzheimer's disease].
de Souza LC; Sarazin M; Uspenskaya O; Habert MO; Lamari F; Lehéricy S; Dubois B
Rev Neurol (Paris); 2012 Nov; 168(11):815-24. PubMed ID: 22944619
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
[TBL] [Abstract][Full Text] [Related]
19. Plasma tau/amyloid-β1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease.
Park JC; Han SH; Yi D; Byun MS; Lee JH; Jang S; Ko K; Jeon SY; Lee YS; Kim YK; Lee DY; Mook-Jung I
Brain; 2019 Mar; 142(3):771-786. PubMed ID: 30668647
[TBL] [Abstract][Full Text] [Related]
20. Commentary on the consensus recommendations for the post mortem diagnosis of Alzheimer's disease.
McLean CA; Beyreuther K; Masters CL
Neurobiol Aging; 1997; 18(4 Suppl):S89-90. PubMed ID: 9330993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
